Menu

Developing life-changing therapies for complex neurological disorders with axonal dysfunction

Therapeutic Focus

Toward a Cure for neuromuscular and neurodegenerative disorders

We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral and central nervous system disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.

We are developing  anovel generation of unique samll molecule therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential therapeutic applications in cardiometabolism, inflammatory and autoimmune diseases.

Learn more about our therapeutic focus

Pipeline

A UNIQUE PIPELINE OF A NOVEL GENERATION OF ORALLY ACTIVE SELECTIVE HDAC6 INHIBITORS

We currently have multiple programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in regulatory preclinical development, while our second and third program are in precinical discovery stage targeting our brain penetrant and peripheral-restricted selective HDAC6i for ALS and cardio-metabolism, respectively.

Discover our pipeline

About Us

Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.

The company is rooted in the groundbreaking research of the laboratory of Professor Ludo Van Den Bosch from the VIB-KU Leuven Center for Brain and Disease Research.

Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.

More about us

Sylvain Celanire, PhD - Chief Executive Officer
Carl Bjartmar, MD, PhD - Chief Medical Officer
Frederik Rombouts, PhD - Vice President, Drug Discovery
Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development

Management

Sylvain Celanire, PhD - Chief Executive Officer

Sylvain has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector

Management

Carl Bjartmar, MD, PhD - Chief Medical Officer

Carl Bjartmar has more than 20 years of experience in clinical research and development of innovative therapies as global pharma and biotech executive

Management

Frederik Rombouts, PhD - Vice President, Drug Discovery

Frederik has 22 years of drug discovery research and development experience in the neuroscience and oncology therapeutic areas

Management

Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development

Cédric has 25 years of experience in preclincial research and early clinical development in the therapeutic areas of inflammation, neurology, fibrosis and oncology

All our team members

News & Events

All articles & events

© 2025 Augustine
A thinline.be | soon production